Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, continues to accelerate clinical trial success for biopharmaceutical and medtech customers through enhanced AI-powered capabilities. Its AI technology has been scaled across the Medidata Platform, benefiting over 500 clinical studies in the last decade, including more than 120 AI-supported studies starting in 2025.
Building on its established AI foundation, Medidata continues to seamlessly weave intelligence into more solutions across its unified platform. The latest advancements include significant enhancements to Medidata Designer with the introduction of Medidata AI Study Build. The new capability accelerates study builds by leveraging the study protocol and generative AI to configure Medidata Rave EDC and Medidata eCOA systems, drastically reducing the time required to move from protocol to start-up. This delivers faster study build times, dramatically speeding time-to-market for sponsors and critical decision-making for CROs.
“Leveraging our large clinical data set from more than 38,000 trials, Medidata's AI is redefining clinical trials, with its impact now evolving from pervasive embedding to quantifiable outcomes,” said Lisa Moneymaker, chief strategy officer, Medidata. “By prioritizing clinically-fluent, regulatory-grade AI to drive results across the trial lifecycle, we are helping our customers turn complexity into clarity and data into decisive action. Our foundational AI engine delivers platform capabilities that allow development teams to focus on resources for advancing patient care.”
To deliver truly intelligent automation, Medidata is accelerating the expansion of Dot, its core AI orchestrator that coordinates and connects the actions of domain specific AI Companions across the platform. The visual presence of Dot enables customers to instantly recognize and access the power of AI built into every step of the clinical trial process. This clear visibility accelerates the use of AI to advance new therapies to patients faster.
To view the original press release, please click here.
